Progesterone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Hormone Replacement Therapy, Infertility Treatment, Menstrual Disorders, Premenstrual Syndrome (PMS), Others), By Region and Competition, 2020-2030F

Market Overview

Global Progesterone Market was valued at USD 203.92 Million in 2024 and is expected to reach USD 242.58 Million by 2030 with a CAGR of 1.89% during the forecast period. Progesterone, a key hormone involved in the reproductive system, is widely used in hormone replacement therapy (HRT), contraceptives, fertility treatments, and veterinary medicine. It plays a crucial role in regulating ovulation and maintaining pregnancy, making it a vital component in both human and animal health applications.

The increasing incidence of infertility is another critical driver. Progesterone is widely used in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) to support the luteal phase and enhance implantation rates. As fertility clinics expand and awareness of ART procedures rises globally, the demand for progesterone-based supplements and medications is expected to climb, particularly in emerging economies. Despite its positive outlook, the market faces challenges such as strict regulatory requirements and the potential side effects associated with long-term progesterone use. Moreover, fluctuations in raw material availability and production costs may affect pricing dynamics.

Key Market Drivers

Growth in Pharmaceutical Industry

The expanding awareness of women's health issues, particularly in relation to menopause, fertility, and hormone imbalances, is significantly contributing to the growth of the progesterone market. AIDS has become a global epidemic, with over 33.2 million individuals affected by HIV. Each day, there are 6,800 new cases and 5,700 deaths. Sub-Saharan Africa remains the hardest-hit region, where half of those living with HIV are women, 76% of whom reside in sub-Saharan Africa, an area with limited access to treatment. As more women seek treatments for conditions such as perimenopause, endometriosis, and polycystic ovary syndrome (PCOS), progesterone plays a crucial role in hormone replacement therapies (HRT) and other pharmaceutical products. The increasing prevalence of age-related hormonal changes has led to a higher demand for progesterone-based treatments, particularly in developed economies, where access to healthcare and treatments is more readily available.

The rising rates of infertility and growing awareness about reproductive health have driven an increase in the demand for fertility treatments, where progesterone is a critical component. Approximately 17.5% of the global adult population, or roughly 1 in 6 individuals, experience infertility, highlighting the urgent need to improve access to affordable, high-quality fertility care. Infertility rates are similar across high-, middle-, and low-income countries, underscoring it as a significant global health challenge. Lifetime prevalence stands at 17.8% in high-income countries and 16.5% in low- and middle-income countries. In assisted reproductive technologies (ART) such as in-vitro fertilization (IVF), progesterone is often used to support embryo implantation and pregnancy maintenance. As the global infertility rate continues to rise, the demand for progesterone-based fertility medications is expected to increase, fueling further growth in the progesterone market. This trend is particularly evident in both developed and emerging economies where access to fertility treatments is expanding.

Surge in Technological Advancements

Technological advancements in drug delivery systems, such as controlled-release formulations and targeted therapies, are revolutionizing the way progesterone is administered. The researchers focused on developing drug delivery systems (DDS) with consistent release rates, self-regulating mechanisms, long-term depot formulations, and nanoparticle-based technologies. While these nanotechnology-driven DDS showed strong efficacy in controlling tumor growth in animal models, only a limited number of drugs have received FDA approval. The development of innovative delivery methods, including transdermal patches, injectable suspensions, and sustained-release oral formulations, has improved patient compliance and the effectiveness of treatments. These delivery systems ensure better bioavailability, reduced side effects, and more consistent therapeutic outcomes, contributing to higher demand for progesterone in hormone replacement therapy (HRT) and fertility treatments.

Technological progress in assisted reproductive technologies (ART) is another significant driver of the progesterone market. Advances in in vitro fertilization (IVF), embryo cryopreservation, and genetic screening have increased the success rates of fertility treatments. As progesterone plays a critical role in supporting early pregnancy and facilitating embryo implantation, these advancements have heightened the demand for progesterone-based therapies. Furthermore, personalized medicine approaches, which involve tailored treatment plans based on genetic and physiological factors, have further fueled the need for precise progesterone therapies in fertility clinics.

Download Free Sample Report

Key Market Challenges

Safety Concerns and Side Effects

For human health, the most notable safety concerns surrounding progesterone treatment are related to its long-term use in women, particularly in HRT and fertility therapies. Common side effects of progesterone include mood swings, headaches, bloating, and fatigue. More serious risks, such as cardiovascular events, thromboembolic disorders, and an increased risk of breast cancer in certain populations, have also been documented, especially when combined with other hormones like estrogen. These health risks raise concerns among both patients and healthcare providers, influencing the prescription patterns of progesterone-based medications.

In fertility treatments, the use of progesterone is critical to supporting the luteal phase and improving the chances of successful implantation in assisted reproductive technologies (ART) like in vitro fertilization (IVF). However, the hormonal imbalance caused by progesterone supplementation may lead to side effects such as ovarian hyperstimulation syndrome (OHSS) or excessive weight gain, which can deter some patients from pursuing such treatments. Additionally, progesterone-induced mood changes or discomfort can impact overall patient experience, affecting the success and continued usage of these treatments.

Key Market Trends

Rise in Menopause Awareness

With growing awareness surrounding menopause, more women are seeking effective solutions to manage symptoms and maintain quality of life. The global population of postmenopausal women is increasing. In 2021, women aged 50 and older represented 26% of the global female population, up from 22% a decade earlier. Furthermore, life expectancy for women is rising, with a 60-year-old woman in 2019 expected to live, on average, another 21 years. As a result, there is a higher demand for hormone replacement therapies (HRT) that include progesterone. Progesterone, often prescribed alongside estrogen, helps reduce the risks associated with estrogen-only therapies, such as endometrial cancer, by balancing the effects of estrogen. This growing preference for balanced HRT formulations is driving the demand for progesterone in menopausal treatment regimens, particularly in developed markets with robust healthcare access.

Bioidentical hormones, which are chemically identical to the hormones produced naturally by the body, have gained significant popularity in the management of menopausal symptoms. As awareness about the potential benefits of bioidentical progesterone has increased, more women are opting for these therapies instead of synthetic alternatives. Bioidentical progesterone is considered a more natural option for managing menopause-related symptoms, making it an attractive choice for patients seeking safer and more effective treatments. This shift toward bioidentical hormone therapies is contributing to the expansion of the progesterone market.

Segmental Insights

Sales Channel Insights

Based on Sales Channel, Direct have emerged as the fastest growing segment in the Global Progesterone Market in 2024. The direct segment offers increased access to progesterone therapies, particularly in markets where traditional distribution channels may be limited or inefficient. By bypassing intermediaries, direct sales enable manufacturers to reach a broader customer base, including hospitals, fertility clinics, and individual patients. This accessibility is particularly beneficial in emerging markets where healthcare infrastructure may not be fully developed.

End Use Insights

Based on End Use, Hormone Replacement Therapy have emerged as the fastest growing segment in the Global Progesterone Market during the forecast period. As the global population continues to age, particularly in developed regions such as North America and Europe, the number of women experiencing menopause is increasing. This demographic shift is driving the demand for HRT, which helps alleviate menopausal symptoms, thus boosting the use of progesterone. There is growing awareness about menopause and its impact on women’s health. This has led to an increase in the adoption of HRT as a preferred treatment option to manage menopausal symptoms, further propelling the growth of progesterone-based treatments.

Download Free Sample Report

Regional Insights

Based on Region, Asia Pacific have emerged as the dominating region in the Global Progesterone Market in 2024. The Asia Pacific region is witnessing a rise in infertility rates, driven by factors such as delayed childbearing, lifestyle changes, and environmental influences. Progesterone, a critical component in assisted reproductive technologies (ART), including in vitro fertilization (IVF), is experiencing a surge in demand as a result. As fertility clinics proliferate across countries like China, India, and Japan, the need for progesterone-based therapies has grown, solidifying the region's dominance in the market.

Recent Development

• As of December 2024, IBSA Institut Biochimique is advancing progesterone through clinical development, currently in Phase III for Female Infertility. Progesterone (marketed as Prontogest, Lutogin, Lubion, Prolutex, Inprosub, Progedex, and Pleyris) is a key progestational steroid primarily secreted by the corpus luteum and placenta. It is available in various formulations, including injectable solutions and powders for intramuscular or subcutaneous administration, as well as oral capsules. IBSA utilizes advanced technologies in the purification process, soft capsule production, hybrid cooperative complexes, topical patches, orodispersible films (ODF), pre-filled syringes, and other delivery methods.
• In May 2025, Besins Healthcare introduced a new progesterone-based treatment in the UK aimed at preventing miscarriage. Marketed as Prometrium, the therapy is intended for women experiencing early pregnancy bleeding or those with a history of recurrent miscarriage. Clinical trials demonstrated a notable improvement in live birth rates. The launch follows the success of the PRISM trial, which evaluated the effectiveness of progesterone in managing early pregnancy complications. Results showed that women receiving progesterone were significantly more likely to carry their pregnancies to term. Among those with three or more prior miscarriages, the risk of miscarriage decreased by 28%, with live birth rates rising to 72%, compared to 57% in the placebo group.
• In May 2024, Jagsonpal Pharmaceuticals Limited announced the launch of MemUp, India’s first hormone replacement therapy (HRT) featuring a US FDA-approved combination of bioidentical estradiol and progesterone in a single daily oral capsule. MemUp marks a significant advancement in women’s healthcare, offering an innovative solution for managing vasomotor symptoms of menopause, such as night sweats, hot flashes, and sleep disturbances. Designed to meet the growing demand for more effective treatment options, MemUp delivers a balanced and natural approach to HRT by closely mimicking the body’s own hormones.
• In December 2024, Zomedica Corp., a veterinary health company specializing in point-of-care diagnostics and therapeutics for companion and equine animals, announced the launch of two new canine assays for its TRUFORMA In-Clinic Biosensor Testing Platform. Among them is a progesterone assay designed for the quantitative measurement of progesterone levels in canine serum. This enables veterinarians to determine optimal breeding times, predict parturition dates, time cesarean sections, and identify reproductive disorders with reference lab-level accuracy delivered conveniently in-clinic. The progesterone assay has been among the most highly requested by practitioners, reflecting strong demand in a market where approximately 4 million puppies are born annually in the U.S.

Key Market Players

• NAARI PHARMA Pvt. Ltd
• La Chandra Pharmalab
• BGP Laboratories Private Limited
• V M Lifescience
• Mankind Pharma Ltd
• Bhugan Lifescience Pvt Ltd
• Abcures Biosciences LLP
• Symbiotec Pharmalab
• Granth Pharma Pvt Ltd
• Emote Lifesciences LLP

Report Scope

In this report, the Global Progesterone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Progesterone Market, By Sales Channel:

o   Direct

o   Indirect

• Progesterone Market, By End Use:

o   Hormone Replacement Therapy

o   Infertility Treatment

o   Menstrual Disorders

o   Premenstrual Syndrome (PMS)

o   Others

• Progesterone Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Progesterone Market.

Available Customizations:

Global Progesterone Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Progesterone Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]